Aignostics develops AI-powered digital pathology solutions that extract diagnostic and research insights from histopathology data. The company's foundation models and Atlas H&E-TME application enable tumor microenvironment profiling and biomarker discovery across pathology workflows. These tools support pharmaceutical development, translational research, and clinical trial platforms designed to meet regulatory requirements.
The company operates with access to pathology samples and multimodal data from over 30 million patients through collaborations with leading university hospitals and laboratories. Aignostics holds ISO 13485 and ISO 27001 certifications, reflecting compliance with medical device and information security standards. Services span target and biomarker discovery, translational research support, and companion diagnostic development.
Aignostics originated as a spin-off from Charité Berlin and works across multiple industry verticals including biopharma, clinical trials, and precision medicine. The company's technical focus spans machine learning, foundation models, data science, and digital pathology applications designed for clinical and research settings.
